New committee to examine safety, rationality of over 300 drugs banned since 2016

NEW DELHI: Over 300 combination medicines banned by the government for being “irrational” or unsafe for consumption will now be examined by a sub-committee under the Drugs Technical Advisory Board (DTAB), according to a new notification by the government. The 300 plus contested drugs include popular brands such as Corex, Phensedyl, D’Cold Total, Vicks Action 500 Extra and Saridon.

This committee is expected to hear arguments supporting the government’s ban as well as those against it before deciding whether companies should be banned from making and selling these medicines, known as fixed dose combinations, here. It may also decide that these drugs should be regulated or restricted to some extent.

The Supreme Court in December directed the committee is required to make its decision by June 2018.

The committee will be headed by Dr Nilima Kshirsagar, chair of clinical pharmacology at the Indian Council of Medical Research, Mumbai, according to the notification.

“The DTAB/sub-committee set up for the purpose will deliberate on the parameters set out in section 26A of the Drugs and Cosmetics Act,” stated Drug Controller General of India GN Singh in a notice dated February 19.

In December 2017, the Supreme Court asked DTAB to decide on the fate of the medicines, banned between March 2016 and June 2017.

The order was a potential relief to drug makers who have argued that the government did not consult statutory bodies provided for in the country’s drug regulations before banning these drugs.

However, if it chooses to, the government could carry out further inquiry on whether these drugs should continue to be marketed in the country, the court added.

  • Related Posts

    Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

    Sarvesh Singh, Director and CEO of Telangana Lifesciences and Pharma, called on industry leaders at a CII Telangana conference to embed safety by design into manufacturing culture, deploying AI, IoT,…

    CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

    Amidst tariff tensions with the US, Europe has created a major opportunity for the Indian pharmaceutical industry. The CDSCO has granted approval to three Indian companies to export APIs to…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

    Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

    CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

    CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

    Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

    Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

    Puducherry drugs inspector suspended after counterfeit medicine crackdown

    Puducherry drugs inspector suspended after counterfeit medicine crackdown

    Researchers discover a compound that can boost ageing muscle repair

    Researchers discover a compound that can boost ageing muscle repair

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks